a real-time in vitro cytolysis assay to evaluate the potency of car t cells

A Real-Time In Vitro Cytolysis Assay to Evaluate the Potency of CAR T Cells

For a real-time cytolysis potency assay, add 50 to 100 microliters of target cell culture medium to each well of an E-plate, and measure the background impedance in the cell-analyzer instrument.
Detach the target cancer cells from the culture plate using trypsin. Wash the cells in 15 milliliters of fresh culture medium and centrifuge. Re-suspend the cancer cell pellet in 5 milliliters of fresh medium for counting and adjust the cell density to the appropriate target cell concentration. Add the cells to the appropriate number of wells, and leave the E-plate for 30 minutes at room temperature to allow the cells to settle evenly on the bottom of the wells.
At the end of the equilibration period, place the plate in the real-time cell-analyzer, and initiate measurement of the impedance automatically every 15 minutes overnight. The adhesion and proliferation of the target cells can be tracked in real-time.
The next morning, dilute the effector CAR and control T cells to the appropriate concentration in individual tubes, and remove 50 to 100 microliters from each well of the E-plate so that the final volume in each well is 100 microliters. Next, see the effector and control T cells in the appropriate wells at the appropriate effector-to-target ratios in 100 microliters of medium per well. Then, equilibrate the plate for 30 minutes at room temperature before returning the plate to the cell-analyzer system.
To measure the efficacy of the T cell-mediated killing of the target cancer cells, monitor the CAR-T cell-mediated killing for 96 hours.

a-real-time-vitro-cytolysis-assay-to-evaluate-potency-car-t

Nanyang Technological University

Research

JoVE Encyclopedia of Experiments

Immunology

Immunodiagnostics

Specialized Assays

EoE Sub Articles

eoe sub articles

1. Generation of CAR-encoding lentivirus
NOTE: Once the specific chimeric antigen receptor (CAR) T-cell plasmid construction is completed (CD47 and others), lentiviral CARs are generated by the standard procedure, using 293 FT cells, a lentiviral packaging mix, and transfection agents (see the&#160;Table of Materials) as described. Subsequently, use a quantitative reverse transcription polymerase chain reaction (RT-PCR) kit and a thermal cycler (see &#160;Table of Materials) to determine the virus titer by measuring the lentiviral RNA amount according to the manufacturer&#39;s protocol. It is important that all lentiviral procedures be carried out strictly following safety requirements.
<ol>
	<li>Seed 15 x 106&#160;HEK293FT cells in Dulbecco&#39;s modified Eagle&#39;s medium (DMEM), and incubate the cells overnight at 37 &#176;C in one 150 mm dish inside a humidified 5% carbon dioxide (CO2) incubator.</li>
	<li>Prepare two 15 mL tubes with transfection complex. The first tube contains lentiviral vector plasmid DNA (5 &#181;g) and lentiviral packaging mix (22.5 &#181;g) in 2.5 mL of transfection dilution solution. The second tube contains 82.5 &#181;L of transfection reagent in 2.5 mL of transfection dilution solution (see the&#160;Table of Materials).</li>
	<li>Pipet the contents of tube 1 into tube 2, and incubate the mixture at room temperature for 15 min.</li>
	<li>Transfer the contents of the tube dropwise to the dish of HEK293FT cells and incubate the sample overnight at 37 &#176;C in a humidified 5% carbon dioxide, CO2&#160;incubator.</li>
	<li>The next day, replace the existing medium with 19 mL of fresh DMEM culture medium and continue to incubate the cells overnight inside the humidified 5% CO2&#160;incubator at 37 &#176;C.</li>
	<li>Transfer the medium from the dish to a 50 mL centrifuge tube. Keep the tube with the virus-containing medium in the refrigerator.</li>
	<li>Repeat the above procedure, adding fresh DMEM and collecting it again after 1 day.</li>
	<li>Combine two collections of the media into one centrifuge tube. Centrifugate the tube at 2,000 x&#160;g&#160;for 30 min at 4 &#176;C.</li>
	<li>Transfer most of the lentivirus-containing supernatant to an ultraclear centrifuge tube. Leave a minimum volume, about 1 mL of the supernatant to avoid disturbing the pellet which may contain cells and/or debris.</li>
	<li>Ultracentrifuge the above-clarified supernatant at 110,000 x&#160;g&#160;for 100 min at 4 &#176;C.</li>
	<li>Remove the supernatant carefully and gently add 100 &#181;L of DMEM medium to the virus pellet at the bottom of the tube. Leave the tube on ice for 15 min. Mix the solution gently and aliquot the lentivirus solution into prechilled sterile tubes. Store these virus stock tubes in a -80 &#176;C freezer.</li>
	<li>Use a quantitative RT-PCR kit to determine the titer of the lentivirus according to the manufacturer&#39;s protocol, which extracts and measures lentiviral RNA.</li>
</ol>
2. Generation and expansion of CAR T cells
<ol>
	<li>Activate previously frozen human peripheral blood mononuclear cells (PBMCs) (about 1 x 106&#160;to 2 x 106&#160;cells) in 1 mL of CAR T-cell medium with an equal number of CD3/CD28-coated microbeads (see the&#160;Table of Materials) and incubate the cells at 37 &#176;C in a humidified 5% CO2&#160;incubator for 24 h.</li>
	<li>Thaw an aliquot of the lentivirus stock on ice.</li>
	<li>Add 1 &#181;L of transduction enhance agent into the well with the cells and mix.</li>
	<li>Add lentivirus to the cells at a multiplicity of infection (MOI) of 5:1 and mix gently. On the next day, repeat this step (24 hours after the first transduction).</li>
	<li>Monitor the T cell growth every 2-3 days. Add more fresh CAR T-cell medium to maintain the cells at a density of 1 x 106&#160;to 2 x 106&#160;cells/mL.</li>
	<li>Freeze down the CAR T cells with a standard protocol using a freezing solution (see the&#160;Table of Materials).</li>
	<li>Thaw CAR T cells using a standard method and preculture them in the CAR T-cell medium for about ~2-4 h with interleukin-2, IL-2 (300 units/mL) before applying them to the assay.</li>
</ol>
3. Detection of CAR expression by flow cytometry
<ol>
	<li>Transfer 3 x 105&#160;CAR T cells and nontransduced T cells to two separate 1.5 mL microcentrifuge tubes.</li>
	<li>Centrifuge the tubes at 300 x&#160;g&#160;for 2 min and resuspend the cells in 200 &#181;L of fluorescence-activated cell sorting (FACS) buffer containing 1% human serum.</li>
	<li>Pipet 100 &#181;L of cell solution into two 5 mL polystyrene FACS tubes and keep the tubes on ice for 5 min.</li>
	<li>Add 1 &#181;L of biotinylated goat anti-mouse F(ab&#39;)2&#160;to one tube of each cell type. Then, add 2 &#181;L of phycoerythrin, a PE-labeled anti-tag antibody (see the&#160;Table of Materials) to the other tube of each cell type. Mix well and incubate them on ice for 30 min.</li>
	<li>Wash the cells with 3 mL of FACS buffer in each tube and centrifuge the tubes at 300 x&#160;g&#160;for 5 min; discard the supernatants and vortex very briefly or shake the tubes briefly to resuspend the cells in the residual liquid.</li>
	<li>Add 2 &#181;L of antigen-presenting cells (APC) anti-CD3 and 2 &#181;L of 7-Aminoactinomycin D (7-AAD) antibody solution (see&#160;Table of Materials) to each tube. In the tube of cells stained with anti-F(ab&#39;)2&#160;Ab, add 1 &#181;L of PE-labeled streptavidin. Mix briefly and incubate the tubes on ice for 30 more min.</li>
	<li>Use FACS buffer to wash the cells again as described in step 3.5 and add an additional 200 &#181;L of FACS buffer to each tube.</li>
	<li>Use flow cytometry to analyze the cells by first gating on the T cells in a forward scatter vs. side scatter plot and then gating on the live cells (7-AAD-negative) in a CD3 vs. 7-AAD plot. The final step is to analyze anti-tag, anti-ScFv, or anti-F(ab&#39;)2&#160;vs. CD3.</li>
</ol>
4. Real-time cytolysis potency assay (RTCA)
NOTE: Perform the RTCA assay according to the manufacturer&#39;s recommended conditions. In brief, first plate the target cells in the wells of the E-Plate, followed by the addition of CAR T cells on the next day. The cytolysis activity of CAR T cells against target cells is monitored in real-time. T cells and mock-transduced T cells (Mock CAR T cells) are used as negative effector cell controls. The following protocol describes an in vitro real-time cytolysis potency assay for adherent tumor cell lines.
<ol>
	<li>Add 100 &#181;L of target cell culture medium to each well of the xCELLigence E-Plate, place the plate inside the xCELLigence instrument, and take a background reading. Then, transfer the E-Plate to a tissue culture hood for cell seeding.</li>
	<li>Use a standard protocol to trypsinize target cancer cells from the culture device. Then transfer the cells to a 15 mL centrifuge tube and add fresh culture medium, up to 15 mL. Pellet the cells by centrifugation for 5 min at 200 x&#160;g. Discard the supernatant, add 5 mL of fresh medium, and use a serological pipette to gently resuspend the cell pellet. Count the density of live cells using a hemocytometer and microscope.</li>
	<li>Adjust the cell density appropriately and then add 100 L of the cell suspension to each well of the E-Plate. The target cell number is typically around 10,000 cells/well for adherent cell lines (BxPC3, Hela-CD19, and SKOV3), or 30,000 cells/well for suspension cells such as Raji (see below for details regarding precoating wells with antibodies in order to tether liquid cancer cells).</li>
	<li>Equilibrate the E-Plate at room temperature for 30 min to allow the cells to settle evenly on the bottom of the well (this is critical; do not skip this step).</li>
	<li>Place the E-Plate into the xCELLigence instrument inside the cell culture incubator and start to measure impedance, displayed as Cell Index vs. time, automatically every 15 min.</li>
	<li>The next day, prepare effector CAR T cells. Make sure to prepare appropriate controls (i.e., Mock CAR T cells, non-transduced control T cells, and/or unrelated CAR T cells) ahead of time to ensure all the cells are ready at the same time. Adjust the effector cells and the control cells to the proper density, and prepare serial dilutions to ensure the desired E:T ratios will be achieved when 100 &#181;L of effector cell suspension is added to each well in step 9.</li>
	<li>Pause xCELLigence data acquisition and bring the E-Plate from the incubator to a cell culture hood.</li>
	<li>Remove 100 &#181;L of medium from each well. The amount of residual medium in each well is now 100 &#181;L.</li>
	<li>Add 100 &#181;L of serially diluted effector CAR T cells or other control cells (i.e. Mock CAR T cells) to achieve the desired E:T ratios.</li>
	<li>Equilibrate the E-Plate at room temperature for 30 min to allow effector cells to settle, and then place the E-Plate back into the xCELLigence instrument. Resume data acquisition.</li>
	<li>If so desired, at key time points xCELLigence data acquisition can be paused and the plate removed in order to collect small samples to be analyzed by orthogonal assays (i.e., measuring cytokine production by enzyme-linked immunosorbent assay (ELISA) or flow cytometry).</li>
	<li>In the EGFR-GITR-CD3 CAR T-cell experiment, measure interferon-gamma (IFN&#947;) yield with an ELISA kit (follow the instructions of the manufacturer; see the&#160;Table of Materials). 
	NOTE REGARDING THE USE OF LIQUID CANCERS: For testing nonadherent hematological cancer cells, prior to adding cells the wells of the E-Plate are first coated with an antibody that is specific for an antigen that is expressed on the surface of the cancer cells. For the Raji B cell line, a tethering reagent based on anti-CD40 is used (see liquid tumor killing assay kit in the&#160;Table of Materials). Below is the procedure for coating the plate:</li>
	<li>Dilute the tethering reagent (anti-CD40) with tethering buffer to a concentration of 4 &#181;g/mL.</li>
	<li>Working inside a tissue culture hood, add 50 &#181;L of the diluted tethering reagent to each well of the E-Plate. Leave the E-Plate at room temperature or in a 37 &#176;C incubator for 3 h.</li>
	<li>Remove the tethering reagent and wash the E-Plate at least 2x with wash buffer. At this point, the E-Plate is ready for seeding the Raji target cells (30,000 cells/well).</li>
	<li>Continue with step 4.1 (above) to perform the rest of the procedure.</li>
</ol>

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>7-AAD</td>
			<td>Biolegend</td>
			<td>420404</td>
			<td></td>
		</tr>
		<tr>
			<td>Anti-CD40, liquid tumor killing assay kit</td>
			<td>ACEA Biosciences</td>
			<td>8100005</td>
			<td></td>
		</tr>
		<tr>
			<td>anti-human F(ab&#39;)2</td>
			<td>Jackson Immunoresearch laboratories.</td>
			<td>109-116-088</td>
			<td></td>
		</tr>
		<tr>
			<td>APC anti-CD3</td>
			<td>Biolegend</td>
			<td>317318</td>
			<td></td>
		</tr>
		<tr>
			<td>Assay medium RPMI1640</td>
			<td>life technologies.Corp</td>
			<td>11875-093</td>
			<td></td>
		</tr>
		<tr>
			<td>CAR-T cell frozen solution CryostorCS10</td>
			<td>Stemcell technologies</td>
			<td>#07930</td>
			<td></td>
		</tr>
		<tr>
			<td>CAR-T cell medium from ProMab</td>
			<td>AIM-V+300IFU/ml IL-2</td>
			<td>12055-091</td>
			<td></td>
		</tr>
		<tr>
			<td>CD3/CD28 coated microbeads, Dynabeads</td>
			<td>Thermofisher</td>
			<td>11131D</td>
			<td></td>
		</tr>
		<tr>
			<td>DMEM</td>
			<td>GElifesciences.com</td>
			<td>SH30243.02</td>
			<td></td>
		</tr>
		<tr>
			<td>FACS buffer</td>
			<td>Promab made</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>FBS</td>
			<td>Lonza.com</td>
			<td>14-503F</td>
			<td></td>
		</tr>
		<tr>
			<td>HEK293FT</td>
			<td>Thermo Fisher</td>
			<td>R70007</td>
			<td></td>
		</tr>
		<tr>
			<td>INFg ELISA kit</td>
			<td>Thermo Fisher</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Lentiviral Packaging Mix</td>
			<td>System Biosciences</td>
			<td>VP100</td>
			<td></td>
		</tr>
		<tr>
			<td>Lenti-X quantitative RT-PCR titration kit (Clontech)</td>
			<td>Takara</td>
			<td>631235</td>
			<td></td>
		</tr>
		<tr>
			<td>Promab medium for target cells</td>
			<td>Varied with cell lines</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Real time Cellular Analyer</td>
			<td>ACEA Biosciences</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Thermal cycler</td>
			<td>Thermo Fisher</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Transduction enhance agent, Virus Transduction Enhancer (Alstem)</td>
			<td>Transplus, Alstem</td>
			<td>V020</td>
			<td></td>
		</tr>
		<tr>
			<td>Transfection dilution solution, Opti-MEM</td>
			<td>Thermo Fisher</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Transfection reagent, NanoFect reagent</td>
			<td>Alstem</td>
			<td>NF100</td>
			<td></td>
		</tr>
	</tbody>
</table>

Source: Xi, B. et al., <a href="https://app-jove-com.remotexs.ntu.edu.sg/v/59033">A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells.</a>&#160;J. Vis. Exp.&#160;(2019)
This video demonstrates a method for monitoring CAR T cell activity against cancer cells through real-time electrical impedance measurements. Tracking changes in impedance assesses the effectiveness of CAR T cells in inducing cancer cell cytolysis, providing insights into their cytotoxic capabilities.

1. Generation of CAR-encoding lentivirus
NOTE: Once the specific chimeric antigen receptor (CAR) T-cell plasmid construction is completed (CD47 and ...

Begin with a cell culture medium-containing E-Plate &#8212; a plate with gold microelectrodes in each well&#39;s bottom.
Seed the plate with target cancer cells, adhering to the gold microelectrodes, forming a physical barrier between the electrodes.
Transfer the plate to a cell analyzer and apply an electrical signal.
Adhered cells disrupt the electron flow between the electrodes, resulting in an impeded flow of electrons, measured as impedance.&#160;&#160;
As these cells proliferate and adhere to the electrodes, electrical impedance increases proportionally with the adherent cell number, enabling real-time measurement.
Introduce chimeric antigen receptor T cells or CAR T cells expressing chimeric antigen receptors. These receptors interact with cancer cells&#39; antigens, activating T cells, and forming an immunological synapse.
Activated CAR T cells release cytotoxic substances, including perforins and granzymes.
Perforins form pores in the cancer cell membrane, facilitating granzymes to enter the cells and induce cytolysis.
This promotes cell detachment, decreasing electrical impedance, correlating with CAR T cells&#39; cytolysis potential.

53 visualizações. Um ensaio de citólise in vitro em tempo real para avaliar a potência das células T CAR

Vídeo: Um ensaio de citólise in vitro em tempo real para avaliar a potência das células T CAR - Experimento

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

The field of chimeric antigen receptor (CAR) T cell therapy is rapidly advancing with improvements in CAR design, gene-engineering approaches and manufacturing optimizations. One challenge for these development efforts, however, has been the establishment of in vitro assays that can robustly inform selection of the optimal CAR T cell products for in vivo therapeutic success. Standard in vitro tumor-lysis assays often fail to reflect the true antitumor potential of the CAR T cells due to the relatively short co-culture time and high T cell to tumor ratio. Here, we describe an in vitro co-culture method to evaluate CAR T cell recursive killing potential at high tumor cell loads. In this assay, long-term cytotoxic function and proliferative capacity of CAR T cells is examined in vitro over 7 days with additional tumor targets administered to the co-culture every other day. This assay can be coupled with profiling T cell activation, exhaustion and memory phenotypes. Using this assay, we have successfully distinguished the functional and phenotypic differences between CD4+ and CD8+ CAR T cells against glioblastoma (GBM) cells, reflecting their differential in vivo antitumor activity in orthotopic xenograft models. This method provides a facile approach to assess CAR T cell potency and to elucidate the functional variations across different CAR T cell products.

Here, we describe an in vitro co-culture method to recursively challenge tumor-targeted T cells, which allows for phenotypic and functional analysis of antitumor T cell activity.

Em Vitro Tumor Cell reexposição para avaliação preditiva de Receptor de antígeno quimérico célula T função antitumoral

The field of chimeric antigen receptor (CAR) T cell therapy is rapidly advancing with improvements in CAR design, gene-engineering approaches and ...

JoVE Journal

Pesquisa do câncer

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Adoptive immunotherapy holds promise for the treatment of cancer and infectious disease. We describe a simple approach to transduce primary human T cells with chimeric antigen receptor (CAR) and expand their progeny ex vivo. We include assays to measure CAR expression as well as differentiation, proliferative capacity and cytolytic activity. We describe assays to measure effector cytokine production and inflammatory cytokine secretion in CAR T cells. Our approach provides a reliable and comprehensive method to culture CAR T cells for preclinical models of adoptive immunotherapy.

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

We describe an approach to reliably generate chimeric antigen receptor (CAR) T cells and test their differentiation and function in vitro and in vivo.

Fabricação de células T do receptor de antígeno quimérico (CAR) para imunoterapia adotiva

Adoptive immunotherapy holds promise for the treatment of cancer and infectious disease. We describe a simple approach to transduce primary human T cells ...

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

T cells genetically engineered to express chimeric antigen receptors (CAR) have shown unprecedented results in pivotal clinical trials for patients with B cell malignancies or multiple myeloma (MM). However, numerous obstacles limit the efficacy and prohibit the widespread use of CAR T cell therapies due to poor trafficking and infiltration into tumor sites as well as lack of persistence in vivo. Moreover, life-threatening toxicities, such as cytokine release syndrome or neurotoxicity, are major concerns. Efficient and sensitive imaging and tracking of CAR T cells enables the evaluation of T cell trafficking, expansion, and in vivo characterization and allows the development of strategies to overcome the current limitations of CAR T cell therapy. This paper describes the methodology for incorporating the sodium iodide symporter (NIS) in CAR T cells and for CAR T cell imaging using [18F]tetrafluoroborate-positron emission tomography ([18F]TFB-PET) in preclinical models. The methods described in this protocol can be applied to other CAR constructs and target genes in addition to the ones used for this study.

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

This protocol describes the methodology for non-invasively tracking T cells genetically engineered to express chimeric antigen receptors in vivo with a clinically available platform.

Imagem dinâmica das células T do receptor de antígeno quimérico com [18F]Tetrafluoroborate Positron Emission Tomography/Tomografia Computadorizada

T cells genetically engineered to express chimeric antigen receptors (CAR) have shown unprecedented results in pivotal clinical trials for patients with B ...

A Real-Time In Vitro Cytolysis Assay to Evaluate the Potency of CAR T Cells

Transcrição

A Real-Time In Vitro Cytolysis Assay to Evaluate the Potency of CAR T Cells